Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06495645

Miss Rate of Gastric Neoplasms Under Computer-aided Endoscopy

This prospective randomized trial compares AI-assisted upper gastrointestinal endoscopy with high definition upper gastrointestinal endoscopy in term of missed rate of gastric neoplasm. The investigators hypothesize the miss rate of high definition upper gastrointestinal endoscopy is higher than AI-assisted upper gastrointestinal endoscopy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Queen Mary Hospital, the University of Hong Kong

Hong Kong

Location status: Recruiting

Location contact

Thomas Ka Luen Lui

CONTACT

[email protected]

+852 97360997

About this study

Patients will be randomly assigned to begin with AI-assisted upper gastrointestinal endoscopy follow immediately by high definition (HD) upper gastrointestinal endoscopy (AI-HD group); or start with HD upper gastrointestinal endoscopy follow immediately by AI-assisted upper gastrointestinal endoscopy (HD-AI group). The random allocation sequence is generated by a computer-generated random numerical series, with 1 representing the AI-HD group and 0 representing the HD-AI group. Randomization is conducted in blocks of four at a 1:1 ratio stratified by indications (screening/surveillance vs others), endoscopist's experience (experienced versus less experienced) and mode of sedation (unsedated vs sedated). Experienced endoscopist is defined as qualified endoscopists with more than 7 years experience in upper endoscopy, whereas less experienced endoscopists include fellows and trainees. A research assistant, not directly involved in this study, maintained all randomization codes which are contained within individual opaque envelopes. Upon obtaining patient consent, the envelope will be opened to reveal the assigned examination sequence. Patients remain blinded to their group allocation throughout the study, but the performing endoscopist is aware of the assigned allocation.

Participating endoscopists will receive training on the interpretation of real-time AI detection system as well as detection of dysplasia under HD endoscopy before performing study. All patients will fast for at least 6 hours before the procedure. All examinations will be performed with HD endoscopes (ELUXEO 7000 video system, Fujifilm Co, Tokyo, Japan) under white light. The artificial intelligence assisted gastric dysplasia localization system uses a graphical user interface for real-time display of lesion detection with bounding boxes (Fujifilm Co, Tokyo, Japan).

Each eligible patient will undergo a same-day tandem upper gastrointestinal endoscopy performed by the same endoscopist to evaluate the miss rate of gastric neoplasm. Patients first receive either AI-assisted or HD upper gastrointestinal endoscopy under white light endoscopy, immediately followed by cross-over to other procedure. Endoscopists will be assisted by a research assistant (RS), who activates or deactivates the lesion detection function of AI system between the two examinations. Both first and second examinations are conducted in accordance with the systematic gastric screening protocol, and only the gastric cavity was rescanned during the second observation. The minimal inspection time of the stomach should be 3 minute for the both examination.

Biopsies of all targeted lesions will be taken at the end of each examination. Endoscopists are instructed to biopsy lesions meeting the following criteria in HD examinations: color differences, loss of vascularity, slight elevation or depression, nodularity, thickening, abnormal convergence or flattening of folds, irregular margins, irregular discoloration, or irregular surface. During AI-assisted examinations, targeted lesions are defined as focal lesions marked in localization boxes. Endoscopists are instructed to biopsy areas stably marked with localization boxes that persisted for 5 seconds by the AI system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 40 or older
  • Scheduled for elective upper endoscopy

Exclusion criteria

  • Pregnant women,
  • Inability to provide written informed consent
  • Prior gastrectomy, and
  • Patients deemed unsuitable or high-risk for endoscopy with severe comorbid illnesses

Treatment and study plan

AI-assisted upper gastrointestinal endoscopy

Device

AI-assisted upper gastrointestinal endoscopy

Primary outcomes

  1. Gastric neoplasia miss rate

    Time frame: during the intervention

    the number of newly detected gastric neoplasia in the second examination divided by the total number of gastric neoplasia detected in both examinations for each patient.

Secondary outcomes

  1. Gastric neoplasia detection rate

    Time frame: during the intervention

    The proportion of patients with one or more gastric neoplasms detected in the first examination

  2. The biopsy rate

    Time frame: during the intervention

    The proportion of patients who had a biopsy sample taken as a result of the first examination

  3. The number of gastric neoplasms per patient

    Time frame: during the intervention

    The total number of gastric neoplasms detected in the first examination divided by the total number of patients

  4. The miss rate of patients with gastric neoplasms

    Time frame: during the intervention

    The number of patients with a newly detected gastric neoplasm in the second examination divided by the total number of patients with gastric neoplasms detected in both examinations

  5. The positive predictive value (PPV) for gastric neoplasms

    Time frame: during the intervention

    The number of detected gastric neoplasms divided by the number of all targeted lesions in the first examination

  6. Inspection time

    Time frame: during the intervention

    The procedure time of the examinations minus the time taken to obtain a biopsy sample, measured from the passage of the endoscope through the gastroesophageal junction until the completion of the whole examination of the gastric cavity, excluding the inspection time of the duodenum and the biopsy time

  7. The macroscopic and histological types of detected and missed neoplasia in the first examination

    Time frame: during the intervention

    The macroscopic and histological types of detected and missed neoplasia in the first examination

  8. Number of biopsy per patient in the first arm

    Time frame: during the intervention

    Number of biopsy per patient in the first arm

  9. Percentage of positive biopsy

    Time frame: during the intervention

    The number of gastric neoplasm detected divided by total number of biopsy in the first arm

Study contacts

Contact information is provided by the study sponsor or research team.

Thomas Ka-Luen Lui

CONTACT

[email protected]

+852 97360997

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Official study title

Computer-aided Gastric Lesion Localization and Miss Rate of Gastric Neoplasms: a Tandem, Randomized Controlled Study

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 11, 2024
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.